CAR-T cell therapy for CEA-positive advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called Anti-CEA-CAR-T cells, which are specially modified immune cells that target a protein called CEA found on certain cancer cells. It is for people with advanced solid tumors, especially digestive system cancers, that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer (like stomach, colorectal, esophageal, or pancreatic) that is advanced or has spread and has high levels of the CEA protein.
- You are between 18 and 69 years old.
- Standard treatments have not worked, are not tolerated, or are not available for your cancer.
- You have at least one tumor that can be measured on scans, and the largest is no bigger than 6 cm.
- Your overall health is good enough for daily activities (ECOG score 0-2) and your blood counts, liver, and kidney function are within certain limits.
- You have not received CAR-T or other gene-modified cell therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
This trial tests a type of immunotherapy called CAR-T, which is designed to recognize and attack cancer cells that have a protein called CEA on their surface. It's for people with advanced cancers like colorectal, esophageal, gastric, pancreatic, lung, or bile duct cancer who have tried at least two standard treatments.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.